95 - Novel Antifungal Olorofim Use in Intractable CNS and Non-CNS Disseminated Coccidioidomycosis

Thursday, October 17, 2024

11:00 AM – 11:15 AM US PT

Location: 403 B

Presenting Author(s)

Fariba Donovan, MD/PhD

Associate Professor
University of Arizona
Tucson, AZ, United States

Slides

Co-Author(s)

George R. Thompson, III, MD

Professor
University of California Davis Medical Center
Sacramento, CA, United States
RJ

Royce H. Johnson, MD

Kern Medical Center
Bakersfield, California, United States
RK

Rasha Kuran, MD

Assistant Professor of Clinical Sciences at David Geffen School of Medicine, UCLA
Kern Medical Center
Bakersfield, California, United States
Thomas F. Patterson, MD (he/him/his)

Professor and Chief, Infectious Diseases
University of Texas Health San Antonio
San Antonio, TX, United States
MH

Martin Hoenigl, MD

Division of Infectious Diseases, Department of Internal Medicine, Medical University of Graz, Graz, Austria
Graz, Steiermark, Austria
Joanna M. Schaenman, MD, PhD, FAST (she/her/hers)

Professor, Department of Medicine, Division of Infectious Diseases
University of California Los Angeles, David Geffen School of Medicine
Los Angeles, California, United States
Shmuel Shoham, MD

Associate Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States
SH

Steven M. Holland, M.D.

Dr.
National Institutes of Health
Bethesda, Maryland, United States
Monica K. Sikka, MD

Associate Professor of Medicine
Oregon Health and Science University
Portland, Oregon, United States
Andrej Spec, MD, MSCI (he/him/his)

Associate Professor
Washington University in St. Louis
St. Louis, MO, United States
MB

Mark Bresnik, MD

Executive Director, Clinical R&D
F2G, Ltd.
Princeton, New Jersey, United States
John N. Galgiani, MD

Director
University of Arizona, Valley Fever Center for Excellence
Tucson, Arizona, United States
John H. Rex, MD

Chief Medical Officer
F2G, Limited
WELLESLEY HILLS, MA, United States

Disclosure(s):

Fariba Donovan, MD/PhD: F2G: Grant/Research Support

George R. Thompson, MD, III: Astellas: Advisor/Consultant (); Cidara: Advisor/Consultant (), Grant/Research Support (); F2G: Advisor/Consultant (), Grant/Research Support (); Melinta: Advisor/Consultant (), Grant/Research Support (); Mundipharma: Advisor/Consultant (), Grant/Research Support (); Pfizer: Advisor/Consultant ()

Royce H. Johnson, MD: No financial relationships to disclose

Rasha Kuran, MD: No financial relationships to disclose

Thomas F. Patterson, MD: F2G: Grant/Research Support ()

Martin Hoenigl, MD: Aicuris: Advisor/Consultant; Astra Zeneca: Honoraria; Gilead: Grant/Research Support, Honoraria; IMMY: Grant/Research Support; Melinta: Grant/Research Support, Honoraria; MSD: Grant/Research Support; Mundipharma: Grant/Research Support, Honoraria; Pfizer: Grant/Research Support; Pulmocide: Advisor/Consultant, Grant/Research Support; Scynexis: Advisor/Consultant, Grant/Research Support; Shionogi: Honoraria

Joanna M. Schaenman, MD, PhD, FAST: Eurofins Viracor: Honoraria; F2G: Grant/Research Support; MedCure: Advisor/Consultant; Moderna: Clinical trial support to institution; OneLegacy: Advisor/Consultant

Shmuel Shoham, MD: F2G: Grant/Research Support

Steven M. Holland, M.D.: No financial relationships to disclose

Monica K. Sikka, MD: F2G: Grant/Research Support

Andrej Spec, MD, MSCI: F2G: Grant/Research Support ()

Mark Bresnik, MD: F2G Ltd: Employee

John N. Galgiani, MD: No financial relationships to disclose

John H. Rex, MD: F2G: Employee